1593. Recurrence of Clostridium difficile Infection in Multiple Myeloma Patients Receiving Prophylactic Oral Vancomycin or Oral Metronidazole vs. No Prophylaxis

BACKGROUND: Multiple myeloma (MM) patients are at increased risk of Clostridium difficile infection (CDI) compared with the general population. In prior studies, 12–14% were diagnosed with CDI, and ~16% had recurrent CDI during subsequent treatments. Recent studies have shown that oral vancomycin is...

Descripción completa

Detalles Bibliográficos
Autores principales: Moran, Gisele, Yarlagadda, Naveen, Susanibar, Sandra, Kothari, Atul, Rico, Juan Carlos, Burgess, Mary J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253229/
http://dx.doi.org/10.1093/ofid/ofy210.1421
_version_ 1783373449751691264
author Moran, Gisele
Yarlagadda, Naveen
Susanibar, Sandra
Kothari, Atul
Rico, Juan Carlos
Burgess, Mary J
author_facet Moran, Gisele
Yarlagadda, Naveen
Susanibar, Sandra
Kothari, Atul
Rico, Juan Carlos
Burgess, Mary J
author_sort Moran, Gisele
collection PubMed
description BACKGROUND: Multiple myeloma (MM) patients are at increased risk of Clostridium difficile infection (CDI) compared with the general population. In prior studies, 12–14% were diagnosed with CDI, and ~16% had recurrent CDI during subsequent treatments. Recent studies have shown that oral vancomycin is effective secondary prophylaxis for the prevention of recurrent CDI in the general population. This retrospective study examined if secondary prophylaxis with oral vancomycin or metronidazole is effective to prevent recurrent CDI in MM patients. METHODS: MM patients who tested positive for their first episode of CDI from January 2014–December 2016 were included, and the 3 months following the CDI diagnosis was reviewed. Patients who died, and those who did not receive additional chemotherapy or antibiotics during the 3-month review period were excluded. The patients were divided into 3 cohorts: (1) oral vancomycin as secondary prophylaxis, (2) oral metronidazole as secondary prophylaxis, and (3) no C. difficile prophylaxis. RESULTS: A total of 110 MM patients with a first episode of CDI were reviewed, six were excluded due to death and four were excluded due to no subsequent chemotherapy or antibiotics. This left 100 patients included for analysis. The median age was 62 years, range 34–81. 92 subjects (92%) had exposure to antibiotics and 76 (76%) received chemotherapy. A total of 38 (38%) received secondary prophylaxis: 16 (42%) with oral metronidazole and 22 (58%) with oral vancomycin. There was no significant difference in recurrent CDI in patients who received any secondary prophylaxis (7/38, 18.4%) and in those who received none (15/62, 24.2%), P = 0.46. Incidence of recurrent CDI in patients receiving oral vancomycin (3/22, 13.6%) was not significantly different from patients receiving oral metronidazole (4/16, 25%), P = 0.56. An analysis of risk factors for recurrent CDI showed no difference in recurrence in patients who received metronidazole vs. vancomycin as treatment for the initial CDI. Similar recurrent CDI occurred in patients who received antibiotics and those who received chemotherapy. CONCLUSION: Secondary prophylaxis with either oral metronidazole or oral vancomycin did not reduce the incidence of recurrent CDI in MM patients. DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6253229
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62532292018-11-28 1593. Recurrence of Clostridium difficile Infection in Multiple Myeloma Patients Receiving Prophylactic Oral Vancomycin or Oral Metronidazole vs. No Prophylaxis Moran, Gisele Yarlagadda, Naveen Susanibar, Sandra Kothari, Atul Rico, Juan Carlos Burgess, Mary J Open Forum Infect Dis Abstracts BACKGROUND: Multiple myeloma (MM) patients are at increased risk of Clostridium difficile infection (CDI) compared with the general population. In prior studies, 12–14% were diagnosed with CDI, and ~16% had recurrent CDI during subsequent treatments. Recent studies have shown that oral vancomycin is effective secondary prophylaxis for the prevention of recurrent CDI in the general population. This retrospective study examined if secondary prophylaxis with oral vancomycin or metronidazole is effective to prevent recurrent CDI in MM patients. METHODS: MM patients who tested positive for their first episode of CDI from January 2014–December 2016 were included, and the 3 months following the CDI diagnosis was reviewed. Patients who died, and those who did not receive additional chemotherapy or antibiotics during the 3-month review period were excluded. The patients were divided into 3 cohorts: (1) oral vancomycin as secondary prophylaxis, (2) oral metronidazole as secondary prophylaxis, and (3) no C. difficile prophylaxis. RESULTS: A total of 110 MM patients with a first episode of CDI were reviewed, six were excluded due to death and four were excluded due to no subsequent chemotherapy or antibiotics. This left 100 patients included for analysis. The median age was 62 years, range 34–81. 92 subjects (92%) had exposure to antibiotics and 76 (76%) received chemotherapy. A total of 38 (38%) received secondary prophylaxis: 16 (42%) with oral metronidazole and 22 (58%) with oral vancomycin. There was no significant difference in recurrent CDI in patients who received any secondary prophylaxis (7/38, 18.4%) and in those who received none (15/62, 24.2%), P = 0.46. Incidence of recurrent CDI in patients receiving oral vancomycin (3/22, 13.6%) was not significantly different from patients receiving oral metronidazole (4/16, 25%), P = 0.56. An analysis of risk factors for recurrent CDI showed no difference in recurrence in patients who received metronidazole vs. vancomycin as treatment for the initial CDI. Similar recurrent CDI occurred in patients who received antibiotics and those who received chemotherapy. CONCLUSION: Secondary prophylaxis with either oral metronidazole or oral vancomycin did not reduce the incidence of recurrent CDI in MM patients. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6253229/ http://dx.doi.org/10.1093/ofid/ofy210.1421 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Moran, Gisele
Yarlagadda, Naveen
Susanibar, Sandra
Kothari, Atul
Rico, Juan Carlos
Burgess, Mary J
1593. Recurrence of Clostridium difficile Infection in Multiple Myeloma Patients Receiving Prophylactic Oral Vancomycin or Oral Metronidazole vs. No Prophylaxis
title 1593. Recurrence of Clostridium difficile Infection in Multiple Myeloma Patients Receiving Prophylactic Oral Vancomycin or Oral Metronidazole vs. No Prophylaxis
title_full 1593. Recurrence of Clostridium difficile Infection in Multiple Myeloma Patients Receiving Prophylactic Oral Vancomycin or Oral Metronidazole vs. No Prophylaxis
title_fullStr 1593. Recurrence of Clostridium difficile Infection in Multiple Myeloma Patients Receiving Prophylactic Oral Vancomycin or Oral Metronidazole vs. No Prophylaxis
title_full_unstemmed 1593. Recurrence of Clostridium difficile Infection in Multiple Myeloma Patients Receiving Prophylactic Oral Vancomycin or Oral Metronidazole vs. No Prophylaxis
title_short 1593. Recurrence of Clostridium difficile Infection in Multiple Myeloma Patients Receiving Prophylactic Oral Vancomycin or Oral Metronidazole vs. No Prophylaxis
title_sort 1593. recurrence of clostridium difficile infection in multiple myeloma patients receiving prophylactic oral vancomycin or oral metronidazole vs. no prophylaxis
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253229/
http://dx.doi.org/10.1093/ofid/ofy210.1421
work_keys_str_mv AT morangisele 1593recurrenceofclostridiumdifficileinfectioninmultiplemyelomapatientsreceivingprophylacticoralvancomycinororalmetronidazolevsnoprophylaxis
AT yarlagaddanaveen 1593recurrenceofclostridiumdifficileinfectioninmultiplemyelomapatientsreceivingprophylacticoralvancomycinororalmetronidazolevsnoprophylaxis
AT susanibarsandra 1593recurrenceofclostridiumdifficileinfectioninmultiplemyelomapatientsreceivingprophylacticoralvancomycinororalmetronidazolevsnoprophylaxis
AT kothariatul 1593recurrenceofclostridiumdifficileinfectioninmultiplemyelomapatientsreceivingprophylacticoralvancomycinororalmetronidazolevsnoprophylaxis
AT ricojuancarlos 1593recurrenceofclostridiumdifficileinfectioninmultiplemyelomapatientsreceivingprophylacticoralvancomycinororalmetronidazolevsnoprophylaxis
AT burgessmaryj 1593recurrenceofclostridiumdifficileinfectioninmultiplemyelomapatientsreceivingprophylacticoralvancomycinororalmetronidazolevsnoprophylaxis